Anika Therapeutics (ANIK) Tops Q3 EPS by 22c

Go back to Anika Therapeutics (ANIK) Tops Q3 EPS by 22c

Anika Reports Third Quarter 2018 Financial Results

October 24, 2018 4:05 PM EDT

CINGAL Drives Strong International Viscosupplement Revenue Growth

Achieves Solid Bottom Line Performance with $0.53 Diluted EPS

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary... More